Could Synthetic Data Predict Rare Adverse Events?
Accenture Surveys Tech Trends In Life Sciences
Executive Summary
Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.
You may also be interested in...
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.
Real World Data Adoption About 10% Amid Challenges: Parexel Executive
While real world data is reliable, synchronization challenges limit its use, Sanjay Vyas, executive vice president and managing director Parexel India tells Scrip in a wide-ranging interview that touches on aspects from synthetic analytics to the interest among Indian companies in developing cell and gene therapies
Sanofi Looks To Atomwise For More AI Help
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.